XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment and Geographic Information
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment and Geographic Information

14.

Segment and Geographic Information

The Company has determined that the chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews financial information presented for the Company’s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.

Geographic Revenues

To provide a more meaningful disclosure along with the developments in its business, the Company changed its methodology of summarizing geographic revenues to be by the region that the revenue is generated, from the previously reported by the bill-to region. Accordingly, the information for the year ended December 31, 2020 and 2019 were recalculated. Geographic revenues, which are based on the region that revenue is generated, are as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Europe

 

$

131,243

 

 

$

17,954

 

 

$

145,641

 

Japan

 

 

2,305

 

 

 

19,824

 

 

 

(23,167

)

China

 

 

55,640

 

 

 

73,361

 

 

 

20,967

 

United States

 

 

46,121

 

 

 

65,180

 

 

 

113,134

 

All other

 

 

—

 

 

 

—

 

 

 

2

 

Total revenue

 

$

235,309

 

 

$

176,319

 

 

$

256,577

 

Geographic Assets

Geographic information for inventory is as follows (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

By geographic location:

 

 

 

 

 

 

 

 

United States

 

$

5,522

 

 

$

1,080

 

China

 

 

25,493

 

 

 

15,450

 

Total inventory

 

$

31,015

 

 

$

16,530

 

 

 

 

 

 

 

 

 

 

By inventory ownership:

 

 

 

 

 

 

 

 

United States

 

$

11,695

 

 

$

4,715

 

China

 

 

19,320

 

 

 

11,815

 

Total inventory

 

$

31,015

 

 

$

16,530

 

Property and equipment, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

United States

 

$

15,002

 

 

$

20,673

 

China

 

 

13,275

 

 

 

12,974

 

Total property and equipment

 

$

28,277

 

 

$

33,647

 

 

 

Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

United States

 

$

730

 

 

$

29,551

 

China

 

 

31

 

 

 

55

 

Total finance lease right-of-use assets

 

$

761

 

 

$

29,606

 

 

 

 

 

 

 

 

 

 

United States

 

$

87,113

 

 

$

47

 

China

 

 

3,999

 

 

 

1,996

 

Total operating lease right-of-use assets

 

$

91,112

 

 

$

2,043

 

Customer Concentration

The Company’s revenues to date have been generated from the following collaboration partners and distribution entity that respectively accounted for 10% or more of the Company’s total revenue and accounts receivable:

 

 

 

Percentage of Revenue

 

 

Percentage of Accounts Receivable

 

 

 

Years Ended December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

2021

 

 

2020

 

Astellas—Related party

 

 

57

%

 

 

21

%

 

 

48

%

 

 

63

%

 

 

10

%

AstraZeneca

 

 

20

%

 

 

37

%

 

 

52

%

 

 

34

%

 

 

26

%

Falikang—Related party

 

 

15

%

 

 

—

%

 

 

—

%

 

 

—

%

 

 

—

%

 

The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. In January 2021, Falikang became fully operational and substantially all direct product sales to distributors in China were made by Falikang, while FibroGen Beijing continued to sell product directly in a few provinces in China during 2021. The aggregate revenue from FibroGen Beijing’s direct sales to distributors for the year ended December 31, 2021 and the aggregate accounts receivable from direct sales to distributors as of December 31, 2021 were immaterial. For the year ended December 31, 2020, the aggregate revenue from distributors represented 42% of the consolidated revenue, with no individual distributor representing over 10% of the total revenue. As of December 31, 2020, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor. The aggregate revenue from distributors for the year ended December 31, 2019 and the aggregate accounts receivable from distributors as of December 31, 2019 were immaterial.